SloveniaThe American healthcare insurance program Medicare has introduced a new initiative allowing elderly Americans access to GLP-1 drugs for obesity treatment at a monthly cost of approximately $50. This marks a significant shift, as limited accessibility was previously a major barrier to wider use of these medications. The drugs Wegovy and Zepbound, produced by Novo Nordisk and Eli Lilly respectively, have become global sales successes and significantly increased the market value of both companies. However, high drug prices had restricted access for many patients. The new Medicare arrangement promises expanded availability. According to research by Goldman Sachs, around 31% of eligible patients could use the program this year, with nearly half expected to participate within a year. Doctors report strong patient interest, with 38% of the eligible population expressing interest in GLP-1 treatments for obesity. The main challenges now involve administrative procedures and obtaining insurance approvals, which doctors identify as the biggest obstacles to faster adoption of these therapies. Analysis suggests that Eli Lilly’s Zepbound would capture approximately 44% of the user base, followed
Bias read (Center): The article provides a balanced overview of the impact of Medicare's new initiative on the pharmaceutical industry, focusing on market dynamics, patient access, and financial projections without overtly favoring any particular perspective.
